Theoretical stack · Cardiometabolic Foundation

Vascular Health & Endothelial Function Stack

Vesugen + Ventfort + Cibinetide

Emerging

Theoretical educational discussion

This page summarizes a peptide combination as discussed in the research and user communities. It does not constitute medical advice, dosing recommendations, or instructions for personal use. Combination-specific human RCT evidence is generally absent for these stacks; per-compound evidence does not transfer additively to combinations.

Decisions about peptide therapy require an appropriately licensed clinician. We do not sell peptides.

At a glance

A vascular-targeted combination drawing on Khavinson's vascular bioregulator program (the older cytomedin Ventfort and the synthetic short-peptide Vesugen) plus cibinetide's documented effects on endothelial and tissue-protective signaling. Distinct mechanisms, modest evidence overall.

Compounds in the stack

Each compound's role in the combination, with link to its full peptide page for the underlying research.

Vesugen
Khavinson short peptide (Lys-Glu-Asp); the synthetic cytogen successor to Ventfort in the vascular bioregulator program
Investigational · Oral
Ventfort
Khavinson cytomedin tissue extract for vascular tissue support; the older cytomedin format
Investigational · Oral
Cibinetide
Non-erythropoietic erythropoietin analog (ARA-290); Phase 2 evidence for tissue-protective and anti-inflammatory effects on the innate-repair pathway
Phase 2 · Investigational

Mechanistic rationale

Endothelial dysfunction is one of the earliest and most consequential changes in cardiovascular aging — preceding atherosclerotic plaque, contributing to hypertension and cognitive decline, and amplifying the impact of metabolic disease. Standard cardiovascular medicine addresses the downstream consequences (statins, antihypertensives, antiplatelets); the upstream endothelial biology has been a more difficult therapeutic target.

This stack combines three peptide approaches to the vascular-aging space. Vesugen and Ventfort both come from the Khavinson program — Ventfort is the older cytomedin (tissue extract), Vesugen the newer cytogen (synthetic short peptide) — both positioned within the framework as supporting vascular and endothelial function. Cibinetide is the most-clinically-developed of the group, with Phase 2 evidence in inflammation-driven indications and a documented mechanism through the innate-repair receptor complex.

Human and emerging evidence

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

Reported user experiences

Potential benefits and risks

Potential benefits

  • Targets a domain (endothelial function) that mainstream cardiovascular medicine has had difficulty addressing directly
  • Cibinetide brings Phase 2 evidence to the combination
  • Khavinson framework offers a coherent theoretical basis for the vascular-bioregulator components
  • Generally well-tolerated profile across all three components

Potential risks

  • For established cardiovascular disease, evidence-based therapy (statins, antihypertensives, antiplatelets, ACE inhibitors) substantially outperforms anything in this stack
  • Khavinson vascular evidence is concentrated in originating lineage with limited Western validation
  • Cibinetide is not approved; access is research-grade and combination interactions are not characterized
  • Endothelial dysfunction has many drivers (lipids, glucose, blood pressure, smoking) — peptide intervention without addressing those drivers is unlikely to produce meaningful outcomes

Open questions

  • Does the stack produce measurable improvements in endothelial-function testing (FMD, PAT) in controlled trials?
  • Does the Khavinson vascular biology hold up under Western-grade independent replication?
  • How does the combination interact with standard cardiovascular pharmacology (statins, antihypertensives)?
  • Are there specific populations (early endothelial dysfunction, post-COVID vascular sequelae) where the combination has differential value?

The takeaway

The Vascular Health stack targets a real and important domain — endothelial function in cardiovascular aging — with peptides that have very different evidence tiers. Cibinetide alone is the most-evidenced of the three. The Khavinson vascular bioregulators are conceptually interesting and lineage-supported but not Western-validated. The honest read: real domain, modest evidence, useful for users curious about the framework but not a substitute for evidence-based cardiovascular medicine in patients with established disease or risk factors.

References

  1. Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2014;20:658-666. https://pubmed.ncbi.nlm.nih.gov/25387363/
  2. Khavinson VK, Linkova NS. Peptide bioregulators: a new class of geroprotectors. Adv Gerontol. 2020;10:34-45. https://pubmed.ncbi.nlm.nih.gov/?term=khavinson+vesugen+ventfort
  3. Heitzer T, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104(22):2673-2678. https://pubmed.ncbi.nlm.nih.gov/11723017/